Advanced Therapies

REGENXBIO
#Advanced Therapies #Adverse event #FDA #Gene therapy #Hunter Syndrome #Phase I trial #REGENXBIO

FDA pauses REGENXBIO’s gene therapies following tumour discovery

The US Food and Drug Administration (FDA) has placed a clinical hold on REGENXBIO’s investigational gene therapy, RGX-111, for the treatment of MPS I, following a single case of neoplasm (intraventricular CNS tumour) in a participant treated in its Phase I/II study.  The FDA also placed a clinical hold on… Read More

#News #Regulatory #Trending News

#Advanced Therapies #Brain cancer #FDA #Gene therapy #Oncology #Phase I trial #Siren Biotechnology

FDA clears first cancer gene therapy for trials

The US Food and Drug Administration (FDA) has cleared Siren Biotechnology’s first Investigational New Drug (IND) application for its AAV immuno-gene therapy for cancer, enabling the initiation of its first-in-human clinical trial.  The IND clearance supports the evaluation of Siren’s lead investigational programme in adult patients with recurrent high-grade glioma.  … Read More

#Cancer Research #Editor's Choice #News #Regulatory

#Advanced Therapies #Collaboration #Eli Lilly #Gene editing #Hearing Loss #Seamless Therapeutics

Lilly’s Seamless gene editing collaboration targets hearing loss

Eli Lilly and Seamless Therapeutics are teaming up to develop and commercialise programmable recombinase-based treatments targeting hearing loss indications, using Seamless’ proprietary recombinase platform.   The company’s technology performs large, precise DNA insertions in any target gene sequence, and operates independent of the cell’s natural DNA repair pathway.  Under the… Read More

#Business & Investment #News

2026 ideas
#Advanced Therapies #Cell and gene therapy #Cell therapy #Drug discovery #Gene editing

CGT in 2026: In vivo, greater specificity and next-gen platforms

What does the coming year hold for advanced therapies? Diana Turner asks industry leaders for their predictions for 2026. 2025 was a mixed year for cell and gene therapies (CGT) with some incredible breakthroughs, but also a withdrawal of many companies from their cell therapy programmes. There is optimism for… Read More

#Exclusive Content #Trends & Analysis

CAR-T cells attacking a cancer cell
#Advanced Therapies #Biotech #CAR T-cell therapy #CARsgen Therapeutics #Dispatch Bio

Biotech collaboration to develop CAR-T therapies 

Biotech companies Dispatch Bio and CARsgen Therapeutics have announced a clinical collaboration to develop innovative CAR-T cell therapies.  The trial will evaluate DISP-11, an investigational therapy leveraging Dispatch’s Flare platform. This includes DV-10, the company’s novel tumour-specific virus, and CARsgen’s zevorcabtagene autoleucel (zevor-cel), an autologous B-cell maturation antigen (BCMA)-targeting CAR-T… Read More

#Business & Investment #News

T cells
#Advanced Therapies #Atara #Cell and gene therapy #Cell therapy #FDA #Pierre Fabre Laboratories

FDA rejects second application for off-the-shelf T-cell therapy

The US Food and Drug Administration (FDA) said it is unable to approve the Atara Biotherapeutics’ off-the-shelf" allogeneic T-cell immunotherapy Ebvallo (tabelecleucel) based on the company’s Biologics License Application (BLA).  The regulator ruled that the single arm ALLELE trial, which Atara’s says was previously confirmed by the FDA as adequate… Read More

#News #Regulatory

CAR-T cell therapy
#Advanced Therapies #CAR-T #Clinical trial #Financing

Vyriad raises $85m to advance CAR-T candidate to clinic 

Biotechnology company Vyriad has closed the final $25 million tranche of its Series B financing round to advance the company’s in vivo CAR-T candidate to clinic.  VV169 has been developed by Vyriad for the treatment of patients with relapsed or treatment-refractory multiple myeloma. The treatment is one of the first in vivo CAR-T candidates leveraging Vyriad’s lentiviral platform, combining an… Read More

#Business & Investment #News

Eye
#Advanced Therapies #FDA #Gene editing #Gene therapy #GenEditBio #Genetic diseases #Ophthalmology #Phase I trial

GenEditBio gets green light for in vivo genome-editing programme

The US Food and Drug Administration (FDA) has cleared GenEditBio to initiate Phase I/II CLARITY trial activities for its lead in vivo genome-editing programme GEB-101 for TGFBI corneal dystrophy.  The Phase 1/2 CLARITY trial will collect initial data on the safety, tolerability and efficacy of GEB-101 in corneal dystrophy patients… Read More

#News #Regulatory #Trending News

#Advanced Therapies #Cell and gene therapy #FDA #Gene therapy #Rare disease

FDA approves first gene therapy for Wiskott-Aldrich syndrome

The US Food and Drug Administration (FDA) has approved Waskyra (etuvetidigene autotemcel), the first cell-based gene therapy for the treatment of Wiskott-Aldrich syndrome (WAS). Waskyra is indicated for paediatric patients six months and older and adults with WAS who have a mutation in the WAS gene and for whom haematopoietic… Read More

#Editor's Choice #News #Regulatory

Diffuse large B-cell lymphoma
#Advanced Therapies #Cancer research #CAR T-cell therapy #Lymphoma #Miltenyi Biotec

CAR-T therapy could treat large B-cell lymphoma 

Biotechnology company Miltenyi Biotec has announced encouraging results from its CAR-T therapy for patients with second-line, relapsed or refractory large B-cell lymphoma.  Primary analysis of candidate zamtocabtagene autoleucel (zamto-cel) showed the therapy demonstrated significant and clinically meaningful superiority over chemoimmunotherapy. The candidate was evaluated in the DALY 2-EU trial, conducted… Read More

#Cancer Research #News

CAR-T for large B-cell lymphoma
#Advanced Therapies #Bristol Myers Squibb #FDA #Haematology #Lymphoma #Oncology

FDA approves first CAR-T therapy for marginal zone lymphoma

The US Food and Drug Administration (FDA) has approved a new indication for Breyanzi (lisocabtagene maraleucel) as the first chimeric antigen receptor (CAR)-T therapy in the US for treatment of adults with marginal zone lymphoma (MZL) who have failed treatment with or relapsed after two or more prior lines of… Read More

#News #Regulatory

#Advanced Therapies #Cell and gene therapy #GlobalData #Investment

Investment shifting in cell and gene therapy, report reveals 

Tighter budgets and company acquisitions have altered investment in the cell and gene therapy (CGT) sector, new analysis finds.  According to a report from data and analytics company GlobalData, the CGT sector is transitioning as companies navigate a more selective and strategy-driven funding landscape.  While venture capital (VC) investment in CGTs… Read More

#Business & Investment #News

Cell and gene therapy
#Advanced Therapies #Cell and gene therapy #Drug development #NHS

eXmoor and NHS trust partner on cell & gene therapies 

Cell and gene therapy CDMO eXmoor Pharma has partnered with Royal Free London NHS Foundation Trust to collaborate on the development and manufacturing of cell and gene therapies in the UK. The collaboration brings together eXmoor’s later-phase clinical manufacturing capabilities  with the trust’s Cell and Vector Innovation Centre (CVIC), which has early-phase clinical manufacturing expertise. The organisations… Read More

#Business & Investment #News

#Advanced Therapies #Cancer research #Cell therapy #Pancreatic cancer

Tumour-regressing cell therapy advanced towards clinic 

Drug discovery company Lunai Bioworks has secured its first Letter of Intent (LOI) to license its next-generation immune cell therapy, advancing the treatment to clinic.  Lunai’s Dendritic Cell Combination Therapy (DCCT) achieved complete regression of both primary and metastatic pancreatic tumours with no recurrence in humanised pre-clinical models. Read More

#Cancer Research #News

#Advanced Therapies #Cell Science #Therapeutic Antibodies

eBook – Your Guide to Faster, Smarter Biologics Testing

Thermal stability testing is essential in biotherapeutic development—ensuring safety, efficacy, and shelf-life. It also helps predict aggregation and guides formulation and storage decisions.   Read this eBook to learn:  Core techniques used in today’s labs Pros and cons of each method How to choose the right solution for your… Read More

#eBooks

#Advanced Therapies #Cancer research

Factsheet – Advance your ADC Research – Organoids Vs. Traditional Models

Unlock insights into ADC development with HUB Organoids’ factsheet on patient-derived organoids. Discover how advanced 3D tumour models are transforming preclinical testing and supporting safer, more effective antibody-drug conjugates. What you’ll learn: How organoids outperform traditional preclinical models for ADCs Strategies for evaluating efficacy, safety, and biomarker discovery Real-world case… Read More